

The background of the top half of the page is a composite image. On the left, there are overlapping purple and green circular shapes. On the right, a circular inset shows a night scene of a city with palm trees in the foreground, a body of water reflecting the lights, and a tall building with many lit windows in the background. The ASH logo, a stylized 'A' and 'S' inside a circle, is faintly visible in the upper right of this inset.

# ASH 2025

## 67th ASH Annual Meeting and Exposition

December 6–9, 2025  
Orlando, United States



## TOP ABSTRACTS

To help navigate the exciting content being presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in lymphoma and CLL.

# ASH 2025: Top abstracts in lymphoma and CLL

December 6–9, 2025

Oral presentations: Saturday, December 6			
Abstract	Title	Presenter	Time (EST)
<b>55</b> <a href="#">View</a>	Ibrutinib plus R-CHOP followed by maintenance in untreated ABC-DLBCL patients with IPI $\geq 2$ : A first analysis of phase II study FIL_RI-CHOP	Alice Di Rocco	09:30–09:45
<b>58</b> <a href="#">View</a>	Results of the primary end-point of the LOC-R01: A randomized phase II study of lenalidomide and ibrutinib in association with rituximab-methotrexate procarbazine vincristin (R-MPV) as a targeted induction treatment for patients aged 18 to 65 with a newly diagnosed primary central nervous system lymphoma (PCNSL)	Carole Soussain	10:15–10:30
<b>61</b> <a href="#">View</a>	Phase II frontline chemolight R-Pola-Glo trial induces high and durable response rates in elderly and medically unfit/frail patients with aggressive B-cell lymphoma	Björn Chapuy	09:30–09:45
<b>62</b> <a href="#">View</a>	Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the phase II MorningSun study	Jeff Sharman	09:45–10:00
<b>63</b> <a href="#">View</a>	Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3	Umberto Vitolo	10:00–10:15
<b>65</b> <a href="#">View</a>	Odronextamab plus chemotherapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): First results from Part 1 of the phase 3 Olympia-3 study	Jean-Marie Michot	10:30–10:45
<b>85</b> <a href="#">View</a>	Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the ongoing phase 1 CaDAnCe-101 study	Inhye Ahn	09:30–09:45
<b>86</b> <a href="#">View</a>	Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed/refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing phase 1a/b trial	Zulfa Omer	09:45–10:00
<b>88</b> <a href="#">View</a>	Results of a registrational phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)	Keshu Zhou	10:15–10:30
<b>151</b> <a href="#">View</a>	3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma	Alex Herrera	12:00–12:15

<b>152</b> <b>View</b>	Final analysis of the phase III GHSG HD21 trial: PET-guided breccadd vs. ebeacopp in advanced-stage classical Hodgkin lymphoma	Justin Ferdinandus	12:15–12:30
<b>155</b> <b>View</b>	First-in-human, open-label, phase 1 study of a novel CD30-directed antibody-drug conjugate with a topoisomerase 1 inhibitor payload, PF-08046044 (35C), in patients with relapsed/refractory lymphomas: Updated safety, PK, preliminary efficacy and ctDNA analysis from dose escalation	Swetha Thiruvengadam	13:00–13:15
<b>223</b> <b>View</b>	Dexamethasone, rituximab and cyclophosphamide with bortezomib is a rapidly acting and highly efficient first-line treatment in Waldenström's macroglobulinemia: Final analysis of ECWM-1 trial of the European Consortium for Waldenström's Macroglobulinemia (ECWM)	Meletios Dimopoulos	14:00–14:15
<b>225</b> <b>View</b>	High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenström macroglobulinemia: Results from a multicenter phase II study	Jorge Castillo	14:30–14:45
<b>226</b> <b>View</b>	Pirtobrutinib in relapsed/refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the phase 1/2 BRUIN study	Chan Cheah	14:45–15:00
<b>227</b> <b>View</b>	Final analysis of the randomized phase 2 ROSEWOOD study of zanubrutinib + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed/refractory follicular lymphoma	Pier Luigi Zinzani	15:00–15:15
<b>228</b> <b>View</b>	Fixed-duration subcutaneous (SC) mosunetuzumab, with maintenance therapy, in patients (pts) with previously untreated high-tumor burden follicular lymphoma (HTB FL): Longer follow-up and exploratory circulating tumor (ct)DNA analysis of the Phase II MorningSun study	John M. Burke	15:15–15:30

### Oral presentations: Sunday, December 7

Abstract	Title	Presenter	Time (EST)
<b>463</b> <b>View</b>	Combined mosunetuzumab and zanubrutinib for the treatment of patients with newly diagnosed high-burden follicular lymphoma: First results of the multicenter phase 2 MITHIC-FL2 trial	Lorenzo Falchi	09:30–09:45
<b>464</b> <b>View</b>	Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial	Reid Merryman	09:45–10:00
<b>465</b> <b>View</b>	Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from EPCORE NHL-2 Arms 6 and 7	Lori Leslie	10:00–10:15
<b>466</b> <b>View</b>	Primary phase 3 results from the EPCORE FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma	Lorenzo Falchi	10:15–10:30
<b>467</b> <b>View</b>	Three-year efficacy and longitudinal safety of lisocabtagene maraleucel (liso-cel) in patients with third-line or later (3L+) follicular lymphoma (FL) from TRANSCEND FL	Sairah Ahmed	10:30–10:45

<b>468</b> <b>View</b>	Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update	Stephen Schuster	10:45–11:00
<b>475</b> <b>View</b>	Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma: Topline efficacy and safety results from the randomized phase 3 DEB study	Wei Li Zhao	09:30–09:45
<b>476</b> <b>View</b>	Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, plus R-CHOP in patients (Pts) with previously untreated aggressive B-cell lymphoma (a-BCL): 24-month efficacy results	Grzegorz Nowakowski	09:45–10:00
<b>477</b> <b>View</b>	Primary analysis of the smart stop trial: Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy in newly diagnosed diffuse large B-cell lymphoma	Jason Westin	10:00–10:15
<b>568</b> <b>View</b>	Biomarker correlates of clinical outcomes from a global phase 1b study of JNJ-90014496, CD20/CD19 bi-specific chimeric antigen receptor (CAR) T-cell therapy for patients with large B-cell lymphoma (LBCL)	Mahipal Suraneni	12:45–13:00
<b>569</b> <b>View</b>	ZUMA-25 preliminary analysis: A phase 2 study of brexucabtagene autoleucel (brexu-cel) in patients (Pts) with relapsed/refractory (R/R) Burkitt lymphoma (BL), substudy C	Suzanne Van Dorp	13:00–13:15
<b>662</b> <b>View</b>	High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 MCL cohort	Marie José Kersten	16:45–17:00
<b>663</b> <b>View</b>	Sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) previously treated with a Bruton tyrosine kinase (BTK) inhibitor: Early results from a phase 1/2 study	Michael Wang	17:00–17:15
<b>664</b> <b>View</b>	Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated mantle cell lymphoma (MAVO)	Austin Kim	17:15–17:30
<b>665</b> <b>View</b>	Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL): Final update from the phase 1/2 BRUIN study	Michael Wang	17:30–17:45
<b>666</b> <b>View</b>	Acalabrutinib plus rituximab followed by brexucabtagene autoleucel for frontline treatment of high-risk mantle cell lymphoma: The WINDOW-3 clinical trial	Preetesh Jain	17:45–18:00
<b>668</b> <b>View</b>	Rondecabtagene autoleucel, an autologous, dual-targeting CD19/CD20 CAR T-cell candidate manufactured from CD62L+ enriched T cells, achieves durable responses in patients with large B-cell lymphoma	Sarah Larson	16:45–17:00
<b>669</b> <b>View</b>	Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for relapsed/refractory large B-cell lymphoma: Primary analysis of the randomized, pivotal DALY 2-EU study	Peter Borchmann	17:00–17:15



<b>670</b> <b>View</b>	Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results	Jason Westin	17:15–17:30
<b>671</b> <b>View</b>	Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a phase 1b study	Dasom (Caroline) Lee	17:30–17:45
<b>679</b> <b>View</b>	MRD-guided ibrutinib plus venetoclax improves outcomes in CLL patients with TP53, ATM, or NOTCH1 aberrations compared to ibrutinib and FCR: Results from the phase III NCRI FLAIR trial	Surita Dalal	16:30–16:45
<b>680</b> <b>View</b>	Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia	Nitin Jain	16:45–17:00
<b>681</b> <b>View</b>	Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized phase II trial for treatment naïve CLL	Mahesh Swaminathan	17:00–17:15
<b>682</b> <b>View</b>	Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the phase III CRISTALLO trial	Hyun Yong Jin	17:15–17:30
<b>683</b> <b>View</b>	Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor	Jennifer Woyach	17:30–17:45
<b>684</b> <b>View</b>	Time-limited acalabrutinib monotherapy in frail patients with previously untreated chronic lymphocytic leukemia: Primary endpoint analysis of the randomized STAIR trial	Romain Guieze	17:45–18:00

### Oral presentations: Monday, December 8

Abstract	Title	Presenter	Time (EST)
<b>775</b> <b>View</b>	Interim analysis of safety and efficacy in a phase 2 study of MB-105, a CD5.CAR T therapy for patients with relapsed/refractory T cell lymphoma	Swami Iyer	10:30–10:45
<b>776</b> <b>View</b>	Liposomal mitoxantrone versus chidamide in relapsed/refractory peripheral T-cell lymphoma: Final analysis from the multicenter, prospective randomized phase 3 study	Huiqiang Huang	10:45–11:00
<b>778</b> <b>View</b>	Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL)	Richard Miller	11:15–11:30
<b>780</b> <b>View</b>	A prospective clinical study on the combination of anti-PD1 monoclonal antibody with lenalidomide and azacitidine for the treatment of relapsed/refractory peripheral T-cell lymphoma	Ting Xu	11:45–12:00
<b>793</b> <b>View</b>	MRD-guided therapy of sonrotoclax (BGB-11417) + obinutuzumab (O) in patients with treatment-naïve CLL: Initial results from an ongoing phase 1/1b study, BGB-11417-101	Marc Hoffmann	10:30–10:45

<b>794</b> <b>View</b>	Optimising MRD-guided treatment: UMRD4 as a half-way treatment timepoint for ibrutinib-venetoclax substantially delays MRD relapse after end of treatment in both IGHV-mutated and IGHV-unmutated CLL	Peter Hillmen	10:45–11:00
<b>795</b> <b>View</b>	Efficacy of 2nd-line treatment in CLL after venetoclax-based 1st-line treatment: Results from the GAIA/CLL13 trial	Carsten Niemann	11:00–11:15
<b>883</b> <b>View</b>	Interim analysis of the phase II study of glofitamab, lenalidomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. Response and safety outcomes after the completion of Stage 1 of 2 enrollment.	Tyrel Phillips	14:45–15:00
<b>884</b> <b>View</b>	Acalabrutinib plus venetoclax and rituximab in patients with treatment-naïve (TN) mantle cell lymphoma (MCL): Results from the phase 2 TrAveRse study	Monique Menzies Wojtowicz	15:00–15:15
<b>885</b> <b>View</b>	Time to third-line treatment after bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Updated analysis of the phase 3 ECHO trial after 50 months of follow-up	Michael Wang	15:15–15:30
<b>888</b> <b>View</b>	Preliminary safety and efficacy of BOVen (zanubrutinib, obinutuzumab, and venetoclax) as frontline therapy for older patients with mantle cell lymphoma	Anita Kumar	16:00–16:15
<b>1004</b> <b>View</b>	Long term follow up of the response adapted FOLL12 trial for patients with advanced stage follicular lymphoma: A study by the Fondazione Italiana Linfomi (FIL).	Stefano Luminari	16:45–17:00
<b>1015</b> <b>View</b>	Epcoritamab combinations demonstrate promising efficacy in patients (pts) with Richter transformation (RT): First results from arms 2B (epcor + lenalidomide [LEN]) and 2C (epcor + R-CHOP) of the phase 1b/2 EPCORE CLL-1 trial	Philip Thompson	16:45–17:00
<b>1017</b> <b>View</b>	Epcoritamab monotherapy demonstrates promising efficacy in patients with Richter transformation (RT): 2-year follow-up results from arm 2A of the phase 1b/2 EPCORE CLL-1 trial	Arnon Kater	16:30–16:45

### Oral presentations: Tuesday, December 9

Abstract	Title	Presenter	Time (EST)
<b>LBA-3</b> <b>View</b>	Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: First results from a randomized phase III study Examining a non-covalent BTK inhibitor in untreated patients	Wojciech Jurczak	08:00–08:15

### Posters

Abstract	Title	Presenter	Time (EST)
<b>5519</b> <b>View</b>	Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO	Jeremy Abramson	Monday, December 8, 18:00–20:00



**#ASH25**

Follow us on X to keep up to date  
with the latest from the congress

**@LymphomaHub**



Brought to you by

